Clinical trials: Hospitalized COVID-19
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19)
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People with Weakened Immune Systems or at Increased Risk for Poor Outcomes who are Hospitalized Due to Severe COVID-19
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization
- Trial name
- EPIC-HOS (NCT05545319)
- Testing
- Nirmatrelvir, Ritonavir
- Where
- 11 sites in United States, Bulgaria
- Sponsor
- Pfizer
Sepsis, Septicemia
A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning
In this study, the investigators will deploy a software-based clinical decision support tool (eCARTv5) into the electronic health record (EHR) workflow of multiple hospital wards.
- Conditions
- Sepsis, Septicemia, Respiratory Failure, Hemodynamic Instability
- Trial name
- NCT05893420
- Testing
- eCARTv5 clinical deterioration monitoring, Standard of care control
- Where
- 3 sites in United States
- Volunteers
- 30,000 people
- Sponsor
- AgileMD, Inc.
COVID-19 Pneumonia
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia
This study (EMPACTA) will a) evaluate the efficacy and safety of tocilizumab (TCZ) compared with a placebo in combination with standard of care (SOC) in hospitalized participants with COVID-19 pneumonia, and b) include an…
- Trial name
- EMPACTA (NCT04372186)
- Testing
- Tocilizumab
- Where
- 44 sites in United States, Brazil and 4 more
- Volunteers
- 377 people
- Sponsor
- Genentech, Inc.
Covid19, Hypoxemia
A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19
Patients with COVID-19 frequently develop lower respiratory complications. Difficulty breathing and a low concentration of oxygen in the blood are of concern in patients with COVID-19, as they indicate that the lungs may be…
- Trial name
- NCT04771000
- Testing
- Ambrisentan
- Where
- 13 sites in Croatia, Spain
- Volunteers
- 88 people
- Sponsor
- Noorik Biopharmaceuticals AG
Infections, Coronavirus
Efficacy and Safety of Polyoxidonium® in Hospitalized Patients With Coronavirus Disease COVID-19
The purpose of this study is to demonstrate the superiority of Polyoxidonium®, lyophilizate for solution for injections and topical application, 6 mg over placebo in hospitalized patients with coronavirus disease (COVID-19).
- Trial name
- NCT04381377
- Testing
- azoximer bromide
- Where
- 14 sites in Russia, Slovakia
- Volunteers
- 394 people
- Sponsor
- NPO Petrovax
COVID-19, ARDS
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19
COVID-19 patients who develop severe disease often develop acute respiratory distress syndrome (ARDS) as a result of a dysregulated immune response.
- Trial name
- NCT04401475
- Testing
- SOC plus 15mg/kg EB05 IV
- Where
- 20 sites in United States, Canada
- Volunteers
- 278 people
- Sponsor
- Edesa Biotech Inc.
COVID-19 Acute Respiratory Distress Syndrome
Safety and Efficacy of Inhaled XW001 For Hospitalized COVID-19 Patients Requiring Oxygen Therapy
This is a multiregional, randomized, double-blind, placebo-controlled Phase 2 study in patients with confirmed symptomatic COVID-19, designed to evaluate the safety, tolerability, efficacy, and PK of XW001 (IL-29 analog)…
- Trial name
- NCT05083117
- Testing
- XW001
- Where
- 2 sites in Argentina, Peru
- Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.
Covid19
Novaferon for COVID-19 Treatment Trial (NCTT-005)
A multicenter, randomized, double-blind, placebo-controlled trial for hospitalized moderate COVID-19 patients
- Trial name
- NCT04708158
- Testing
- Novaferon
- Where
- 22 sites in Japan
- Volunteers
- 385 people
- Sponsor
- Genova Inc.
COVID-19
Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19
This is a proof of concept study to evaluate the efficacy of nitazoxanide (600 mg BID) to treat hospitalized patients with moderate COVID-19.
- Trial name
- NCT04348409
- Testing
- Nitazoxanide Tablets
- Where
- 3 sites in Brazil
- Volunteers
- 50 people
- Sponsor
- Azidus Brasil
COVID-19
A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia
The primary objective of this study is to evaluate the efficacy of CKD-314 (Nafabelltan) compared to standard of care (SOC), with respect to clinical status assessed by a 7-point ordinal scale in hospitalized adult patients…
- Trial name
- NCT04623021
- Testing
- Nafamostat Mesilate
- Where
- 11 sites in Russia
- Volunteers
- 104 people
- Sponsor
- Chong Kun Dang Pharmaceutical
COVID-19
Safety and Pharmacokinetics of FBR-002 for the Treatment of Patients Hospitalized With COVID-19 in Need of Supplemental Oxygen and at Risk of Severe Outcome
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the coronavirus associated with COVID-19 (Coronavirus Disease 2019), invading the respiratory tract, and leading to symptoms from dysgeusia, anosmia, fever, headache…
- Trial name
- NCT05279352
- Testing
- FBR-002
- Where
- 6 sites in Greece
- Volunteers
- 30 people
- Sponsor
- Fab'entech
COVID-19
An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19
The study is Phase II/III and consists of pilot and pivotal stages. The objective of the pilot stage is to conduct a preliminary assessment of the efficacy and safety of Favipiravir, and to select the optimal dosing regimen to…
- Trial name
- NCT04434248
- Testing
- Favipiravir, Standard of Care
- Where
- 22 sites in Russia
- Volunteers
- 330 people
- Sponsor
- Chromis LLC
SARS-CoV-2 Infection
A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19
The main aim of this study is to evaluate the efficacy of S-217622 versus placebo among outpatient adults with mild and moderate COVID-19 starting intervention within 3 days of symptom onset.
- Trial name
- SCORPIO-HR (NCT05305547)
- Testing
- S-217622
- Where
- 196 sites in United States, Argentina and 15 more
- Volunteers
- 2,093 people
- Sponsor
- Shionogi
COVID-19
A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19
Study of EDP-235 in Non-hospitalized Adults with Mild or Moderate COVID-19.
- Trial name
- SPRINT (NCT05616728)
- Testing
- EDP-235
- Where
- 23 sites in United States, Romania
- Volunteers
- 231 people
- Sponsor
- Enanta Pharmaceuticals, Inc
Acute Kidney Injury, Covid19
Renal Involvement in Hospitalized Children With COVID-19
Covid-19 is an important human and animal pathogen, it mostly causes respiratory and gastrointestinal symptoms. Clinical features range from a common cold to severe diseases such as severe acute respiratory distress syndrome…
- Conditions
- Acute Kidney Injury, Covid19, Renal Dysfunction, Coronavirus Infection
- Trial name
- RIHCC (NCT04788394)
- Testing
- data review, data comparing
- Where
- Qatar
- Volunteers
- 400 people
- Sponsor
- Hamad Medical Corporation
COVID19, COVID-19
PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer
This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pacritinib in hospitalized patients with severe COVID-19 with or without cancer.
- Conditions
- COVID19, COVID-19, COVID
- Trial name
- NCT04404361
- Testing
- Pacritinib
- Where
- 21 sites in United States
- Volunteers
- 200 people
- Sponsor
- CTI BioPharma
Covid19
Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19
Sequential randomized, multicenter, active comparator study to evaluate the hypothesis that rNAPc2 (AB201), a novel, potent and highly selective tissue factor inhibitor with anticoagulant, anti-inflammatory and potential…
- Trial name
- ASPEN (NCT04655586)
- Testing
- rNAPc2, Heparin
- Where
- 24 sites in United States, Argentina and 1 more
- Volunteers
- 160 people
- Sponsor
- ARCA Biopharma, Inc.
Identify the Viral Epitopes of Memory CD8 T Cells From Individuals That Have Recovered From SARS-CoV-2 Infection, Determine Which SARS-CoV-2 Proteins Are Frequently Recognized by T Cells in Patients With Varying HLA Types
Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes
The COVID-19 pandemic is a global emergency threatening to take millions of lives in the United States and around the world. There is no current vaccine strategy against COVID-19 infection caused by a novel coronavirus named…
- Trial name
- NCT04397900
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- TScan Therapeutics, Inc.
COVID-19
Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19
The primary objective of the study is to determine if Prolastin plus SMT can reduce the proportion of subjects dying or requiring intensive care unit (ICU) admission on or before Day 15 or who are dependent on invasive mechanical…
- Trial name
- NCT04495101
- Testing
- Prolastin, Standard Medical Treatment
- Where
- 9 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Instituto Grifols, S.A.
COVID-19
A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients
The purpose of this study is to assess the safety and efficacy of Alvesco (ciclesonide) Inhalation Aerosol in non hospitalized patients with symptomatic COVID-19 infection in a multicenter, randomized, double-blind, placebo…
- Trial name
- NCT04377711
- Testing
- Ciclesonide
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Covis Pharma S.à.r.l.